European Congress of Rheumatology 2021 (EULAR 2021) VIRTUAL

virtual 02 June 2021 - 05 June 2021

Apremilast improves Behçet’s syndrome-related oral ulcers in both sexes

24 Jun 2021 by

The use of apremilast consistently reduced the number and pain due to oral ulcers in both men and women with active Behçet’s syndrome, according to a subgroup analysis of the RELIEF* study presented at EULAR 2021.

Apremilast improves Behçet’s syndrome-related oral ulcers in both sexes

24 Jun 2021

TNFi treatment in rheumatic disease not a risk for COVID-19 hospitalization

23 Jun 2021 by

Analysis of the German COVID-19 registry suggests that patients with rheumatic or musculoskeletal diseases (RMDs) who are treated with tumour necrosis factor (TNF) inhibitors appear to be at lower risk of severe outcomes of COVID-19 compared with those treated with other (non-TNF inhibitor) immunomodulatory treatments (OIDs).

TNFi treatment in rheumatic disease not a risk for COVID-19 hospitalization

23 Jun 2021

Certain rheuma therapies tied to poorer COVID-19 outcomes, impaired vaccine response

19 Jun 2021 by

Certain therapies used for rheumatic diseases, including rituximab, are associated with worse outcomes for COVID-19 and reduced immune response after COVID-19 vaccination in patients with rheumatic diseases, according to two studies presented at the virtual EULAR 2021 Congress.

Certain rheuma therapies tied to poorer COVID-19 outcomes, impaired vaccine response

19 Jun 2021

Secukinumab promising for paediatric enthesitis-related arthritis and juvenile psoriatic arthritis

18 Jun 2021 by

Treatment with the fully human anti-IL17 monoclonal antibody secukinumab resulted in fewer, and a longer time to, disease flares in children and adolescents with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA), results of the phase III JUNIPERA trial showed.

Secukinumab promising for paediatric enthesitis-related arthritis and juvenile psoriatic arthritis

18 Jun 2021

COSMOS: Guselkumab improves response rates in active psoriatic arthritis

18 Jun 2021 by

Treatment with guselkumab improved response rates in patients with active psoriatic arthritis (PsA) who had inadequate responses to tumour necrosis factor (TNF) inhibitors, according to the COSMOS* study presented at EULAR 2021.

COSMOS: Guselkumab improves response rates in active psoriatic arthritis

18 Jun 2021

COVID-19 vaccine safe in people with rheumatic diseases

17 Jun 2021 by

Data from the EULAR COVID-19 Vaccination (COVAX) Registry showed that available COVID-19 vaccines were safe and well tolerated in patients with rheumatic and musculoskeletal diseases (RMDs).

COVID-19 vaccine safe in people with rheumatic diseases

17 Jun 2021

Mavrilimumab improves outcomes in nonventilated patients with severe COVID-19, hyperinflammation

17 Jun 2021 by

The human monoclonal antibody mavrilimumab reduced the rates of mechanical ventilation and death in nonmechanically ventilated patients with severe COVID-19 pneumonia and systemic hyperinflammation, according to a phase II/III study presented at EULAR 2021.

Mavrilimumab improves outcomes in nonventilated patients with severe COVID-19, hyperinflammation

17 Jun 2021

KEEPsAKE2 trial reveals potential of risankizumab for psoriatic arthritis

16 Jun 2021 by

The humanized immunoglobulin G1 monoclonal antibody risankizumab led to significant improvements in patients with active psoriatic arthritis (PsA), including those with insufficient response or intolerance to one or two biologic therapies or to at least one DMARD*, according to the results of the phase III KEEPsAKE2 trial presented at EULAR 2021.

KEEPsAKE2 trial reveals potential of risankizumab for psoriatic arthritis

16 Jun 2021

Iberdomide confers dermatologic benefit for SLE

15 Jun 2021 by

A high dose of the high-affinity cereblon ligand iberdomide delivered beneficial effects on the cutaneous manifestations of systemic lupus erythematosus (SLE), according to a phase II study presented at EULAR 2021.

Iberdomide confers dermatologic benefit for SLE

15 Jun 2021

Secondhand smoke may up RA risk

09 Jun 2021 by

Exposure to secondhand smoke, regardless of whether it is during childhood or adulthood, is associated with an increased risk of developing rheumatoid arthritis (RA) among women — particularly in those who never smoke themselves, according to data from the E3N-EPIC study presented at the EULAR 2021 Congress.

Secondhand smoke may up RA risk

09 Jun 2021